Literature DB >> 12587099

Stopping clinical trials because of treatment ineffectiveness: a comparison of a futility design with a method of stochastic curtailment.

John Whitehead1, Tatsuru Matsushita.   

Abstract

This paper introduces a simple futility design that allows a comparative clinical trial to be stopped due to lack of effect at any of a series of planned interim analyses. Stopping due to apparent benefit is not permitted. The design is for use when any positive claim should be based on the maximum sample size, for example to allow subgroup analyses or the evaluation of safety or secondary efficacy responses. A final frequentist analysis can be performed that is valid for the type of design employed. Here the design is described and its properties are presented. Its advantages and disadvantages relative to the use of stochastic curtailment are discussed. Copyright 2003 John Wiley & Sons, Ltd.

Mesh:

Year:  2003        PMID: 12587099     DOI: 10.1002/sim.1429

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  8 in total

Review 1.  Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.

Authors:  Toshimitsu Hamasaki; Scott R Evans; Koko Asakura
Journal:  J Biopharm Stat       Date:  2017-10-30       Impact factor: 1.051

2.  Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints.

Authors:  Koko Asakura; Toshimitsu Hamasaki; Scott R Evans
Journal:  Biom J       Date:  2016-10-19       Impact factor: 2.207

3.  Stopping clinical trials early for futility: retrospective analysis of several randomised clinical studies.

Authors:  M Jitlal; I Khan; S M Lee; A Hackshaw
Journal:  Br J Cancer       Date:  2012-08-09       Impact factor: 7.640

4.  Evaluating clinical trial designs for investigational treatments of Ebola virus disease.

Authors:  Ben S Cooper; Maciej F Boni; Wirichada Pan-ngum; Nicholas P J Day; Peter W Horby; Piero Olliaro; Trudie Lang; Nicholas J White; Lisa J White; John Whitehead
Journal:  PLoS Med       Date:  2015-04-14       Impact factor: 11.069

5.  Automated psychological therapy using virtual reality (VR) for patients with persecutory delusions: study protocol for a single-blind parallel-group randomised controlled trial (THRIVE).

Authors:  Daniel Freeman; Rachel Lister; Felicity Waite; Ly-Mee Yu; Mel Slater; Graham Dunn; David Clark
Journal:  Trials       Date:  2019-01-29       Impact factor: 2.279

6.  Bayesian modeling and simulation to inform rare disease drug development early decision-making: Application to Duchenne muscular dystrophy.

Authors:  Janelle L Lennie; John T Mondick; Marc R Gastonguay
Journal:  PLoS One       Date:  2022-04-28       Impact factor: 3.240

7.  Trial design for evaluating novel treatments during an outbreak of an infectious disease.

Authors:  John Whitehead; Piero Olliaro; Trudie Lang; Peter Horby
Journal:  Clin Trials       Date:  2016-01-14       Impact factor: 2.486

8.  Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial.

Authors:  Jake Dunning; Foday Sahr; Amanda Rojek; Fiona Gannon; Gail Carson; Baimba Idriss; Thomas Massaquoi; Regina Gandi; Sebatu Joseph; Hassan K Osman; Timothy J G Brooks; Andrew J H Simpson; Ian Goodfellow; Lucy Thorne; Armando Arias; Laura Merson; Lyndsey Castle; Rebecca Howell-Jones; Raul Pardinaz-Solis; Benjamin Hope-Gill; Mauricio Ferri; Jennifer Grove; Mark Kowalski; Kasia Stepniewska; Trudie Lang; John Whitehead; Piero Olliaro; Mohammed Samai; Peter W Horby
Journal:  PLoS Med       Date:  2016-04-19       Impact factor: 11.069

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.